title: Feasibility of central cannabinoid CB1 receptor imaging with [124I]AM281 PET demonstrated in a schizophrenic patient.
abstract: We studied central cannabinoid CB1 receptors in a schizophrenic patient using the pyrazole derivative AM281 labelled with the positron-emitting nuclide iodine-124. A dynamic positron emission tomography (PET) acquisition with simultaneous blood sampling was performed up to 1.5 h post-injection. The classical Logan plot analysis was applied to generate a three-dimensional map of distribution volume (DV). The map was spatially normalised into the Montreal Neurological Institute stereotactic space. Using a volume of interest (VOI) template, mean values of DV were extracted from multiple grey matter regions and white matter (as a reference). As a measure of regional receptor availability, ratios of DV in grey matter to DV in white matter minus one (DVR-1) were calculated. The highest receptor binding was observed in the striatum and the pallidum (DVR-1: 0.35-0.37). Binding in basal ganglia regions was lower on the left than the right side. Moderately high binding was seen in the frontal cortex (0.22), the temporal cortex (0.18) and the cerebellum (0.15). In conclusion, 124I-AM281 PET can be used to reveal areas with prominent CB1 receptor binding. Nevertheless, limited image contrast and relatively high radiation exposure (physical half-life of 124I: 4 days) have to be taken into account. Asymmetric receptor binding may possibly reflect pathologic changes in schizophrenia.
authors.affiliation: Department of Nuclear Medicine, University School of Medicine, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany. berding.georg@mh-hannover.de
authors.forename: Georg
authors.initials: G
authors.lastname: Berding
authors.forename: Udo
authors.initials: U
authors.lastname: Schneider
authors.forename: Peter
authors.initials: P
authors.lastname: Gielow
authors.forename: Ralph
authors.initials: R
authors.lastname: Buchert
authors.forename: Frank
authors.initials: F
authors.lastname: Donnerstag
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Brandau
authors.forename: Wolfram H
authors.initials: WH
authors.lastname: Knapp
authors.forename: Hinderk M
authors.initials: HM
authors.lastname: Emrich
authors.forename: Kirsten
authors.initials: K
authors.lastname: Müller-Vahl
mesh_terms: D001921:Brain / Q000000981:diagnostic imaging* / Q000378:metabolism*; D005240:Feasibility Studies; D006801:Humans; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics*; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000493:pharmacokinetics*; D049268:Positron-Emission Tomography; D011720:Pyrazoles / Q000493:pharmacokinetics*; D043884:Receptor, Cannabinoid, CB1 / Q000378:metabolism*; D012559:Schizophrenia / Q000000981:diagnostic imaging*
chemical_list: D007457:Iodine Radioisotopes; D009025:Morpholines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; C109925:AM 281